baber/WOPTO huggingface dataset:
Patent NZ-569108-A (NZ)
Title: Formulations of CTLA4Ig stabilised using sugars
Inventor: DALI MANISHA M
IPC: A61P19/02
Filed: 2006-12-19
Abstract: A stable formulation of CTLA4Ig that is suitable for subcutaneous administration. The formulation comprises: (1) 100mg/ml CTLA4Ig molecules shown in SEQ ID NO: 2 starting at methionine at position 27 or alanine at position 26 and ending at lysine at position 383 or glycine at position 382; (2) A sugar selected from sucrose, lactose, maltose, mannitol and trehalose and mixtures thereof; and (3) A pharmaceutical aqueous carrier. The formulation has a pH from 6 to 8 and is stable when stored at 2 to 8 degrees Celsius for 12 months. The formulation can be used to manufacture a medicament for treating an autoimmune disease, immunoproliferative disease and graft-related disorders.
Patent NZ-571824-A (NZ)
Title: Amylin family peptides and methods for making and using them
Inventor: HANLEY MICHAEL R
IPC: C07K14/585
Filed: 2005-02-11
Abstract: Provided is a specified amylin family peptide and its variants as well as their use in the manufacture of medicaments for treating eating disorders, diabetes, cardiovascular diseases and other diseases. (62) Divided Out of 549332
Patent NZ-571956-A (NZ)
Title: Telecommunications jack with circuit board that connects contact springs to wire termination contacts
Inventor: HAMMOND BERNARD
IPC: H01R13/66
Filed: 2007-04-10
Abstract: Disclosed is a telecommunications jack (120) with crosstalk compensation. The jack comprises: a housing (122, 124, 126) defining a port (128) for receiving a plug; a plurality of contact springs adapted to make electrical contact with the plug when the plug is inserted into the port of the housing; a plurality of wire termination contacts for terminating wires to the jack; and a circuit board that electrically connects the contact springs to the wire termination contacts. The circuit board includes first (140) and second (142) conductive layers separated by a first dielectric layer (146), the first dielectric layer having a thickness less than .01 inches. The first and second conductive layers include a cross talk compensation arrangement including spaced-apart capacitor members, the capacitor members being separated by the first dielectric layer.
Patent NZ-572259-A (NZ)
Title: Hla alleles associated with adverse drug reactions and methods for determining whether a patient carries said alleles
Inventor: CHEN YUAN-TSONG
IPC: C12Q1/68
Filed: 2007-05-11
Abstract: Disclosed is a method of assessing a risk of a human patient for developing an adverse drug reaction in response to a drug, comprising detecting the presence of HLA-B*1502 in a sample obtained from the patient, and correlating the presence of HLA-B*1502 in the sample with an increased risk for an adverse drug reaction in the patient in response to the drug, wherein the adverse drug reaction is Stevens-Johnson syndrome or toxic epidermal necrolysis and the drug is oxcarbazepine.
Patent NZ-575571-A (NZ)
Title: Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
Inventor: CAI ZELING
IPC: C12N5/0783
Filed: 2007-10-04
Abstract: Disclosed is a method for creating activated T lymphocytes ex vivo for administration to a patient, comprising the steps of: inactivating Drosophila artificial antigen presenting cells (Drosophila aAPCs) with a nucleic acid crosslinking agent, wherein the nucleic acid crosslinking agent comprises a psoralen selected from the group consisting of 8-methoxypsoralen (8-MOPS), 4'- (aminomethyl)-4,5', 8-psoralen (AMT), or amotosalen (S59), and wherein said inactivating step comprises exposing the Drosophila aAPCs treated with the psoralen to a photo activating dose of UVA irradiation, contacting T lymphocytes isolated from the patient with said inactivated Drosophila aAPCs thereby creating activated T lymphocytes; and collecting the activated T lymphocytes for administration back to the patient. Also disclosed is a psoralen-inactivated Drosophila artificial antigen presenting cell (Drosophila aAPC), wherein the Drosophila aAPC expresses HLA-A2.1, B7-1 (CD80), LFA- 3(CD58), CD70 and ICAM-l (CD54) cell surface proteins and presents the following peptides: YMNGTMSQV (SEQ ID NO:5), ITDQVPFSV (SEQ ID NO:7), AAGIGILTV (SEQ ID NO:9), ELAGIGILTV (SEQ ID NO:10), SLLMWITQV (SEQ ID NO:27), FL WGPRAL V (SEQ ID NO:30), TLAKFSPYL (PRAME; SEQ ID NO:54) and VLDGLDVLL (SEQ ID NO:71).
Patent NZ-577540-A (NZ)
Title: New process for the synthesis of 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid (benzazapine, benzazapinone)
Inventor: LERESTIF JEAN-MICHEL
IPC: C07C231/02
Filed: 2009-06-09
Abstract: Disclosed is a process for the synthesis of the compound of formula (I), 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one, which comprises starting with the compound (3,4-dimethoxyphenyl)acetic acid, the compound of formula (IV), converting it into the amide of formula (V), then, without isolating compound (V), subjecting it to a cyclisation reaction to obtain compound (I). Also disclosed is the use of the compound of formula (I) for the synthesis of ivabradine.
Patent NZ-577547-A (NZ)
Title: Reactor system for producing gaseous products
Inventor: CORTRIGHT RANDY D
IPC: C01B32/50
Filed: 2007-12-20
Abstract: Disclosed herein is a concurrent downflow reactor system when used for converting a liquid feedstock to a non-condensable gas product using a heterogeneous catalyst, the reactor comprising: · a reacting chamber comprising at least one reaction tube containing a heterogeneous catalyst therein; · an inlet configured to provide a pressure Pi and adapted to feed the liquid feedstock to an upper portion of the reaction chamber; · an outlet configured to provide a pressure Po and adapted to discharge the non-condensable gas product and an effluent stream from a lower portion of the reaction chamber; and · wherein the reactor is configured such that in use Pi is greater that Po.
Patent NZ-579982-A (NZ)
Title: Light weight additive, method of making and uses thereof
Inventor: HOJAJI HAMID
IPC: C04B12/04
Filed: 2008-04-16
Abstract: Disclosed is a low density additive comprising particles of a low density inorganic material having a porous structure with hydroxyl groups deposited on its surface to provide hydrophilic and reactive sites on the surface and one or more hydrocarbon chains oriented on the surface, the particles being between 0.1 /lm to 15 mm in size, and the low density additive having a positive zeta potential and a bulk density of between 60 to 1000 kg/m3. Also disclosed is a method for making a low density additive. .
Patent NZ-580169-A (NZ)
Title: Detection of mutations in a gene associated with resistance to viral infection, OAS1 (SEQ ID NO:48)
Inventor: IADONATO SHAWN P
IPC: A61K31/7088
Filed: 2004-10-22
Abstract: Disclosed is a polypeptide encoding a mutated oligoadenylate synthetase 1 (OAS 1). This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also disclosed is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS 1, including antisense oligonucleotides, methods, and compositions specific for human OASI, are also provided.
Patent NZ-584606-A (NZ)
Title: An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
Inventor: SALAZAR ONFRAY FLAVIO ANDRES
IPC: A61K35/12
Filed: 2008-09-26
Abstract: Disclosed isan ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases. At the same time, it is related to a cellular composition that contributes to stimulate the activated antigen-presenting cells to induce a specific immune response against tumors in patients with cancer or other pathologies involving immune responses.
Patent NZ-585881-A (NZ)
Title: Inflatable wing for traction kite with inflatable spar spaced from leading edge
Inventor: ROAKE RICHARD JOHN
IPC: B63B35/79
Filed: 2010-06-02
Abstract: An inflatable wing for a traction kite is disclosed having a leading edge and a trailing edge, and with a flexible sheet envelope, and an inflatable spar within the envelope extending spanwise and being spaced apart from the leading edge.
Patent NZ-586890-A (NZ)
Title: Hydrodynamic energy generation using buoyant device with different density fluids
Inventor: KWOK JAMES
IPC: F03B17/02
Filed: 2008-12-19
Abstract: An energy generation system comprising at least one shaft, buoyant means associated with, and movable relative to, said at least one shaft, wherein movement of the buoyant means relative to said at least one shaft causes rotation of the at least one shaft about a longitudinal axis, means for adding and/or removing a fluid to and/or from said buoyant means to cause movement of the buoyant means, and power generation means associated with said at least one shaft.
Patent NZ-589415-A (NZ)
Title: Compositions comrpising TGF-beta-1, BMP4, alpha-thrombin, cardiotrophin and cardiogenol c
Inventor: TERZIC ANDRE
IPC: A61K35/28
Filed: 2009-05-20
Abstract: Disclosed is a composition comprising TGF â-1, BMP4, a-thrombin, Cardiotrophin, and Cardiogenol C.
Patent NZ-592361-A (NZ)
Title: A roller door that can be more tightly rolled due to a hinge allowing greater pivoting between door panels
Inventor: SVENSON MIKE
IPC: E05D1/04
Filed: 2011-04-19
Abstract: Disclosed is a hinge assembly for a roller door allowing a tighter roll to be formed that uses less volume. The hinge assembly comprises a hinge member, first and second panels and at least one retainer. The hinge member hingedly interconnects the first and second panels to one another to allow relative pivoting movement of the panels with respect to each other. The first and second panels are each elongate and comprise first and second curved hinge elements at respective first and second edges of each panel, with one of the curved hinge elements curving in a first direction and the other curved hinge element curving in a second direction. The hinge member is elongate and has opposing inner and outer surfaces, opposing first and second edges and opposing first and second ends. The hinge member also comprises a first curved slot located towards the second edge for receiving the first curved element of the first panel and a second curved slot located towards the first edge for receiving the second curved hinge element of the second panel. The hinge member also comprises a coupling portion at least one of the first and second ends, the retainer configured to be coupled in one of the coupling portions so as to retain the curved hinge elements of the panels in respective first and second curved slots of the hinge member. The first slot has an opening that defines an abutment portion for the first panel to abut when the first curved hinge element is rotated partially out of the first curved slot.
Patent NZ-596033-A (NZ)
Title: A low carbon welded tube and process of manufacture thereof
Inventor: SANJAY HARISHCHANDRA WAGHULADE
IPC: B21C37/08
Filed: 2010-04-23
Abstract: 596033 A process for manufacturing a cold rolled, low carbon, welded tube is disclosed. The process includes: strip cutting and forming as per the desired final tube size; subjecting the formed strip to high frequency induction welding along the seam to produce a hollow. An induction welding coil in the proximity of the hollow induces a magnetic field that is concentrated on the open seam by an impeder disposed inside the hollow. The open seam is fused via the induction welding coil to complete the welding process to produce the hollow; heat treating the hollow; cold rolling the hollow between cam shaped profiled rolls and a mandrel that is disposed inside the hollow. The hollow and the mandrel are rotated about the longitudinal axis as the hollow advances between the said profiled rolls and the mandrel is then moved back and the process is repeated for next segment of the hollow; The process results in a reduction in energy consumption, and at the same time enhances the quality of the resulting tubes with improved dimensional stability, closeness of tolerance, reduced thickness variation, concentricity and reduction in material wastage.
Patent NZ-599763-A (NZ)
Title: Tablet formulations of neratinib maleate
Inventor: ASHRAF MUHAMMAD
IPC: A61K9/20
Filed: 2010-11-02
Abstract: The disclosure relates to a pharmaceutically acceptable composition comprising: a granulation comprising intragranular components: (a) 10-70 weight percent neratinib maleate; (b) 15-65 weight percent of one or more fillers; (c) 0-8 weight percent of one or more disintegrants; and (d) 0.2-8 weight percent of one or more glidants; and (e) 5-15 weight percent of one or more surface modifying agents, wherein the granulation is combined with extragranular components (f) 1-25 weight percent of one or more fillers; (g) 0-8 weight percent of one or more disintegrants and (h) 0.1-3 weight percent of one or more lubricants. Also disclosed is a method for preparing a pharmaceutically acceptable composition comprising: (1) spraying 5-15 weight percent of one or more surface modifying agents onto intragranular components of a granulation, said intragranular components comprising: (a) 10-70 weight percent neratinib maleate; (b) 15-65 weight percent of one or more fillers; (c) 0-8 weight percent of one or more disintegrants; and (d) 0.2-8 weight percent of one or more glidants; and (2) combining said coated intragranular components with extragranular components of a granulation, said extragranular components comprising (e) 1-25 weight percent of one or more fillers; (f) 0-8 weight percent of one or more disintegrants and (g) 0.1-3 weight percent of one or more lubricants.
Patent NZ-600363-A (NZ)
Title: Modified porcine somatotropin polypeptides and their uses
Inventor: KNUDSEN NICK
IPC: C07K14/475
Filed: 2010-12-21
Abstract: Discloses a porcine somatotropin (pST) polypeptide comprising the amino acid sequence of SEQ ID NO: 1, wherein the amino acid at position 92 of SEQ ID NO: 1 is substituted for a non-naturally encoded amino acid.
Patent NZ-600454-A (NZ)
Title: Fibronectin: growth factor chimeras
Inventor: UPTON ZEE
IPC: C07K14/78
Filed: 2010-11-30
Abstract: Discloses a protein complex in the form of a synthetic chimeric protein comprising an amino acid sequence of (I) an insulin-like growth factor (IGF, IGF-I or IGF-II) or at least a domain of said insulin-like growth factor which is capable of binding a cognate insulin-like growth factor receptor and (II) one or more type-III domains of fibronectin (FN3) comprising at least an integrin-binding domain of FN3; wherein the complex is suitable for stimulating cell migration and/or proliferation
Patent NZ-603193-A (NZ)
Title: Antibodies that bind csf1r
Inventor: WONG JUSTIN
IPC: C12N5/10
Filed: 2011-05-04
Abstract: Disclosed is an isolated antibody that binds human CSF1R, comprising a heavy chain and a light chain of CDR sequences as defined in the specification. Also disclosed is the use of the said antibody in the manufacture of a medicament for treating cancer, autoimmune diseases, inflammatory conditions, or osteolytic bone loss.
Patent NZ-619401-A (NZ)
Title: Support system
Inventor: HASELDEN STUART
IPC: H05K7/14
Filed: 2011-03-08
Abstract: A support system (1) for substantially isolating an object (100) from abrupt movement of a foundation. The support system has a frame (3) operatively attached to the foundation and a cradle (11) for supporting the object. The support system also has a horizontal isolation component (5) and a vertical isolation component (7). The horizontal isolation component is configured to allow movement of the frame relative to the foundation and dampen movement of the object in a horizontal direction during abrupt movement of the foundation. The vertical isolation component is operatively connected between the frame and the cradle. The vertical isolation component is configured to allow movement of the cradle relative to the frame in a vertical direction and dampen movement of the object in a vertical direction during abrupt movement of the foundation. The horizontal isolation component and the vertical isolation component are arranged such that dampening of movement of the object in one of the horizontal and vertical directions is uncoupled from the dampening of movement of the object in the other of the horizontal or vertical directions.
Patent NZ-624258-A (NZ)
Title: Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
Inventor: TCHELET AMIR
IPC: C12Q1/68
Filed: 2012-10-09
Abstract: A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier is disclosed comprising the step of determining the genotype of the subject at one or more single nucleotide polymorphisms (SNPs), identifying the subject as a predicted responder or non-responder to glatiramer acetate based on the determined SNP genotype, and administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
Patent NZ-628789-A (NZ)
Title: Electronic smoking article
Inventor: KASOFF VICTOR
IPC: A24F40/48
Filed: 2013-02-22
Abstract: A manually pumped electronic cigarette is disclosed. The cigarette (10) includes a capillary tube (18) in communication with a liquid supply (14) including liquid material and a heater (19) operable to heat the capillary tube to a temperature sufficient to vaporize the liquid material contained therein and form an aerosol. The liquid supply is adapted to be squeezed or otherwise compressed so as to allow a smoker to manually pump liquid to the capillary tube and simultaneously activate the heater. A pressure switch (44) is used to sense the pumping action and enable power from the power supply (12) to energise the heater.
Patent NZ-701121-A (NZ)
Title: Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
Inventor: WILMEN ANDREAS
IPC: C07K16/36
Filed: 2013-05-08
Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.
Patent NZ-701424-A (NZ)
Title: Anti -transglutaminase 2 antibodies
Inventor: JOHNSON TIM
IPC: C12N15/13
Filed: 2013-05-24
Abstract: The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.
Patent NZ-706357-A (NZ)
Title: Method of producing metal-coated steel strip
Inventor: NEUFELD AARON KIFFER
IPC: C23F15/00
Filed: 2013-10-17
Abstract: A method of forming a coating of an Al-Zn-Si-Mg alloy on a steel strip to form an Al-Zn-Mg-Si coated steel strip is disclosed. The method includes the steps of dipping steel strip into a bath of molten Al-Zn-Si-Mg alloy and forming a coating of the alloy on exposed surfaces of the steel strip and cooling the coated strip with cooling water. The cooling step includes controlling the pH of cooling water to be in a range of p H 5-9. Particular embodiments focus on Al-Zn-Si-Mg alloys that contain the following elements in % by weight: Zn: 30 to 60, Si: 0.3 to 3, Mg: 0.3 to 10, and Balance Al and unavoidable impurities.
Patent NZ-708009-A (NZ)
Title: A method of disinfecting a surface
Inventor: JAMES OWEN LESTER
IPC: A61L2/16
Filed: 2015-05-11
Abstract: A method of disinfecting a surface comprising the step of applying to the surface a composition comprising triethyl borate and wherein the surface is disinfected against bacteria and/or fungi after the composition has been applied to it.
Patent NZ-708028-A (NZ)
Title: N-pyrrolidinyl, n’-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
Inventor: ALLEN SHELLEY
IPC: C07D401/12
Filed: 2013-11-12
Abstract: Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren’s syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
Patent NZ-712885-A (NZ)
Title: Wind turbine control system
Inventor: ILLING WES
IPC: F03D7/04
Filed: 2014-03-11
Abstract: Sudden changes in wind velocity and/or direction can overstress and damage components and result in premature failure of a wind turbine. The present invention provides an automated pitch control system that manages energy extracted from the wind using an electro-mechanical or electromechanical-hydraulic system which alters blade pitch to prevent damaging torque levels. The wind turbine includes a hub sub-system comprising a main hub and a shaft adapted to rotate about an axis, and a plurality of turbine blades having a pitch angle. The blades are adapted to drive the rotation of the hub sub-system to a first speed. The wind turbine further includes a pitch drive sub-system including a drive element adapted to rotate about the axis at a second speed, and further adapted to control the pitch angle of the turbine blades in relation to a difference between the first speed and the second speed.
Patent NZ-714379-A (NZ)
Title: Immobilization of an active agent on a substrate using compounds including trihydroxyphenyl groups
Inventor: HAI TON
IPC: A61L27/54
Filed: 2014-06-06
Abstract: The invention provides methods of immobilizing an active agent to a substrate surface. In one particular embodiment there is provided a method of immobilising chitosan on a substrate, comprising the steps of: providing a substrate with a surface, the substrate surface comprising a surface of a medical device or medical device component, and the substrate is selected from the group consisting of polysulfone, polyisoprene, polycarbonate, and polydimethylsiloxane; activating the substrate by treating the substrate surface with an oxidizing agent, or irradiating the substrate in the presence of an initiator to generate a radical on the substrate surface; contacting the activated substrate with a solution of gallic acid, wherein the solution further comprises bicene; and contacting the gallic acid-treated substrate with chitosan as an active agent, thereby covalently bonding the chitosan to the gallic acid and immobilizing the chitosan on the substrate. In an alternative embodiment there is also provided a method of immobilizing polyethylene glycol (PEG) as an antifouling agent onto a metal surface of a substrate, comprising the steps of: providing a medical device or medical device component with a surface comprising a metal; contacting the substrate with a solution of gallic acid, wherein the solution further comprises bicene; and contacting the gallic acid-treated substrate with polyethylene glycol (PEG) as an antifouling agent, thereby covalently bonding the PEG to the gallic acid and immobilizing the PEG on the substrate.